“Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s379. doi:10.25251/skin.8.supp.379.